Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.
British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
British Journal of Haematology|March 9, 2011
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaLetizia Foroni, Gill Wilson, Gareth Gerrard, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Blood|March 15, 2012
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapiesAndreas Agathangelidis, Nikos Darzentas, Anastasia Hadzidimitriou, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Nature|July 20, 2010
Regulation of myeloid leukaemia by the cell-fate determinant MusashiTakahiro Ito, Hyog Young Kwon, Bryan Zimdahl, et al.
Blood|December 1, 2007
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)Anthony H Goldstone, Susan M Richards, Hillard M Lazarus, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Blood|February 27, 2009
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993Adele K Fielding, Jacob M Rowe, Susan M Richards, et al.
British Journal of Haematology|March 29, 2020
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trialChezi Ganzel, Xin V Wang, Jacob M Rowe, et al.
Blood|December 16, 2006
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trialAnthony V Moorman, Christine J Harrison, Georgina A N Buck, et al.
British Journal of Haematology|March 9, 2011
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemiaLetizia Foroni, Gill Wilson, Gareth Gerrard, et al.
Blood|December 11, 2012
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsJamshid S Khorashad, Todd W Kelley, Philippe Szankasi, et al.
Blood|March 15, 2012
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapiesAndreas Agathangelidis, Nikos Darzentas, Anastasia Hadzidimitriou, et al.
Pageof 9